PHARMAC

📣 Pharmac is funding life changing treatments for people with cystic fibrosis, including children.

From 1 April 2026, access will be widened to two existing medicines, and a new medicine will be funded, helping people with cystic fibrosis live longer, healthier lives.

Thank you to everyone who shared feedback - your input helped shape this decision.

🔗https://www.pharmac.govt.nz/news-and-resources/news/2026-03-media-release-pharmac-to-fund-lifechanging-treatments-for-children-with-cystic-fibrosis

🩺 New treatment options proposed for people with chronic lymphocytic leukaemia (CLL)

Today we opened consultation on a proposal to fund two new targeted treatment combinations for people with previously untreated chronic lymphocytic leukaemia (CLL), a type of blood cancer.

If approved, funding would begin from 1 May 2026 for:
• venetoclax with ibrutinib
• venetoclax with obinutuzumab

These treatments could help people achieve longer‑lasting remission, reduce the need for chemotherapy, and improve quality of life.

We’re seeking feedback from people living with CLL, their whānau, health professionals, and the wider community. Consultation is open until 5pm, Wednesday 4 March.

👉 Find out more and have your say:

Pharmac proposes funding new treatments that could transform early care for people with chronic lymphocytic leukaemia, a type of blood cancer Pharmac proposes funding new treatments that could transform early care for people with chronic lymphocytic leukaemia, a type of blood cancer 18 February 2026 Media release Medicines At a glance Pharmac is proposing to fund two new treatment combinations - venetoclax with ibrutinib, and venetoclax w...

🎤Have your say on our proposal to widen access to brentuximab for people with systemic anaplastic large cell lymphoma (sALCL) from 1 April 2026.

Pharmac proposes wider access to a treatment for people with a rare blood cancer Pharmac proposes wider access to a treatment for people with a rare blood cancer 4 February 2026 Media release Medicines At a glance Pharmac is proposing to widen access to brentuximab vedotin for people with systemic anaplastic large cell lymphoma (sALCL) from 1 April 2026. Under the proposal, bren...

📣 Pharmac is making a change to ensure everyone who needs HIV medicines can access them more easily.

From 1 March 2026, all HIV medicines will be able to be dispensed in three-month amounts (rather than monthly), reducing pharmacy visits and making it easier for people to manage their treatment.

🔗 Find out more: bit.ly/4rhsu9f

Decision to enable three monthly (STAT) dispensing for HIV medicines Decision to enable three monthly (STAT) dispensing for HIV medicines 27 November 2025 Medicines Decision What we’re doing We're pleased to announce that from 1 March 2026 Pharmac will be enabling more flexible supply via all at once dispensing (known as STAT or 3 monthly dispensing) for all anti...